ROR1

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 7, 2023
Science, Research, NR4A3, CAR, NSCLC, IND, Literature, Colorectal cancer, ROR1, G&A, Workforce, GSK plc, GAAP, Phenotype, TIL, R, Lyell, TNBC, SITC, Immunotherapy, Clinical trial, Wine Cellar Innovations, Abstract, GSK, Triple-negative breast cancer, Lung cancer, Society, Patient, Pharmaceutical industry, Vaccine, Medical imaging

An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.

Key Points: 
  • An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.
  • Lyell is advancing four wholly-owned product candidates with two product candidates in Phase 1 clinical development, LYL797 and LYL845.
  • Non‑GAAP G&A expenses, which exclude non-cash stock-based compensation, for the third quarter ended September 30, 2023, were $9.5 million, compared to $11.4 million for the same period in 2022.
  • The decrease in third quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal, consulting and other administrative expenses.

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
TCE, Drug resistance, ROR1, Society, Hematology, CLL, Lymphoid neoplasms with plasmablastic differentiation, PK, Risk, Abstract, MCL, MRD, Trichloroethylene, Pharmacology, Autoregulation, CRS, Safety, AR, Manchester Grand Hyatt Hotel, Patient, Toxicity, Cerebral autoregulation, Mantle cell lymphoma, Therapeutic index, Birth control, Pharmaceutical industry

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough immunotherapies, alongside an Autoregulation platform, today announces the online publication of two abstracts submitted to the American Society of Hematology Annual meeting, to be held December 9-12, 2023 in San Diego, USA.

Key Points: 
  • “We are pleased to announce our forthcoming oral presentation on the hematological arm of the NVG-111-01 Phase I clinical study (NCT04763083).
  • Building upon these achievements, we are advancing the development of NVG-111 into solid tumor indications,” said Professor Amit Nathwani, Founder and CEO of NovalGen.
  • This mitigates adverse events but also facilitates the administration of higher doses over extended durations, thereby expanding the therapeutic index.
  • NovalGen have shown that applying AR to TCEs does not affect the potency, but significantly reduces toxicity in pre-clinical models.

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

Retrieved on: 
Monday, September 11, 2023
GMP, Triple-negative breast cancer, TAP, Immunotherapy, Lung cancer, CAR, Patient, SAN, Cell, Integrated development environment, SDM, Automation, ROR1, Mobile phone, Vaccine, Lyell, Zasmidium cellare

Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.

Key Points: 
  • Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
  • As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell’s LYL797 CAR T-cell therapy, using the Cell Shuttle.
  • Cellares' innovative manufacturing technology transforms autologous and allogeneic cell therapy processes, covering nearly 90% of cell therapy modalities.
  • Through their TAP program, Cellares can facilitate the automation and tech transfer of manual processes onto the Cell Shuttle manufacturing platform in just six months.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Retrieved on: 
Tuesday, August 8, 2023
GSK, GSK plc, TIL, ISSCR, Clinical trial, Lyell, G&A, GAAP, Research, Biomarker, Lung cancer, NR4A3, Organization, CAR, Patient, Colorectal cancer, SAN, Corporation, Annual general meeting, Growth, CAR T cell, R, International Society for Stem Cell Research, IND, International Society, ROR1, Pharmaceutical industry, Management, Vaccine, Medical imaging

Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022.

Key Points: 
  • Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022.
  • Revenue was approximately zero for the second quarter ended June 30, 2023, compared to $35.7 million for the same period in 2022.
  • The decrease in second quarter 2023 G&A expenses was primarily driven by changes in non-cash stock-based compensation.
  • The decrease in second quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal, consulting and other administrative expenses.

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Retrieved on: 
Monday, June 26, 2023
Partnership, Streptococcus, Senior, BX, TD, ReFrame, Platinum, Sutro, Blackstone, Patient, SAN, Peterborough, STRO, PCV, Spacecraft, Ovarian cancer, NYSE, ROR1, Fine chemical

SOUTH SAN FRANCISCO, Calif and NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), and Blackstone (NYSE: BX), today announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront, with up to an additional $250 million in future milestone payments triggered at various return thresholds, in exchange for Sutro’s 4% royalty, or revenue interest, in the potential future sales of Vaxcyte’s products, including VAX-24 and other products that Vaxcyte develops under its license with Sutro.

Key Points: 
  • - Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future milestone payments in exchange for the royalty, or revenue interest, in potential future sales of Vaxcyte’s products -
    SOUTH SAN FRANCISCO, Calif and NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), and Blackstone (NYSE: BX), today announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront, with up to an additional $250 million in future milestone payments triggered at various return thresholds, in exchange for Sutro’s 4% royalty, or revenue interest, in the potential future sales of Vaxcyte’s products, including VAX-24 and other products that Vaxcyte develops under its license with Sutro.
  • Vaxcyte’s lead candidate, VAX-24, is a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine (PCV) with enhanced serotype coverage and immunogenicity.
  • Vaxcyte’s PCV franchise is enabled by Sutro’s XpressCF® cell-free protein synthesis technology.
  • “We established an important and valued partnership with Blackstone Life Sciences through this transaction, while continuing to capitalize on the value generated from the technologies underlying our cell-free protein synthesis and conjugation platforms,” said Bill Newell, Sutro’s Chief Executive Officer.

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma

Retrieved on: 
Tuesday, June 6, 2023
CD19, Lymphoma, Cell, Aggressive lymphoma, CAR, Patient, SAN, MD Anderson Cancer Center, Therapy, ROR1, Pharmaceutical industry

“We are excited to announce the first patient, who had failed previous CD19 CAR T therapy, has been treated with ONCT-808,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.

Key Points: 
  • “We are excited to announce the first patient, who had failed previous CD19 CAR T therapy, has been treated with ONCT-808,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
  • “We believe ONCT-808 has the potential to produce robust and durable responses for patients suffering from aggressive lymphoma.
  • Preclinical models show robust and specific activity against ROR1 expressing cells from multiple tumor types.
  • Oncternal has developed a manufacturing process that is reproducible, scalable, and only 8 days in duration.

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Wednesday, May 17, 2023
Ionization, Spermine, Myelocyte, DNA, Gene, Macrophage, Gene editing, Cancer, Lipid, NK, Research, Cell, Los Angeles Convention Center, Element, Messenger, AAVS1, Acquisition, Patient, ERNA, Blood, Immune system, Entrepreneurship, LNP, Cytotoxicity, IPS, Safety, Society, ROR1, Vaccine, Antibiotics, Eterna

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, and its discovery partner Factor Bioscience (“Factor”) today announced new data on an iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, as well as advances in nucleic-acid delivery and targeted gene insertion, in eight poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center.

Key Points: 
  • “This approach has the potential to form the foundation of an entirely new class of cell therapies that could play an important role in treating cancer.
  • In vitro studies with lymphoid and myeloid cells showed synergistic killing of SKOV3 ovarian tumor cells.
  • This methodology has the potential to support the development of engineered cell therapies designed to express therapeutic proteins.
  • The data presented show that the lipids identified may serve as components of next-generation, LNP-based mRNA and gene therapies.

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

Retrieved on: 
Thursday, May 4, 2023
GSK, GSK plc, Gene, TIL, Lyell, G&A, GAAP, Research, Lung cancer, CAR, Patient, Colorectal cancer, Annual general meeting, Cell, AP-1 transcription factor, R, IND, Society, American Society of Gene and Cell Therapy, ROR1, Vaccine, Cryptocurrency, Mobile phone, Pharmaceutical industry, Medical imaging

Lyell reported a net loss of $67.0 million for the first quarter ended March 31, 2023, compared to a net loss of $68.1 million for the same period in 2022.

Key Points: 
  • Lyell reported a net loss of $67.0 million for the first quarter ended March 31, 2023, compared to a net loss of $68.1 million for the same period in 2022.
  • Revenue was $0.1 million for the first quarter ended March 31, 2023 compared to $0.6 million for the same period in 2022.
  • The decrease in first quarter 2023 G&A expenses was primarily driven by changes in non-cash stock-based compensation.
  • The decrease in first quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal expenses.

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
ROR1, BTK, Investigational New Drug, Investment, Patient, SAN, MCL, Research, FDA, Therapy, IND, AR, Prostate cancer, Pharmaceutical industry

“Oncternal is intensely focused on advancing our cell therapy and androgen receptor (AR) inhibitor programs to reach significant clinical inflection points over the coming months.

Key Points: 
  • “Oncternal is intensely focused on advancing our cell therapy and androgen receptor (AR) inhibitor programs to reach significant clinical inflection points over the coming months.
  • Our total operating expenses for the first quarter ended March 31, 2023 were $12.3 million, including $1.9 million in non-cash stock-based compensation expense.
  • Research and development expenses for the quarter totaled $9.0 million, and general and administrative expenses for the quarter totaled $3.3 million.
  • Net loss for the first quarter was $11.5 million, or a loss of $0.20 per share, basic and diluted.

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Retrieved on: 
Thursday, April 27, 2023
ReFrame, SAN, STRO, ADC, Spacecraft, Coronavirus Scientific Advisory Board, Synthetic biology, ROR1, Pharmaceutical industry, Management

“On behalf of Sutro, we would like to thank Trevor for his twelve years of scientific leadership and contributions to our innovative science—most recently as President of Research & Chief Scientific Officer and as a member of our senior management team,” said Bill Newell, Sutro’s Chief Executive Officer.

Key Points: 
  • “On behalf of Sutro, we would like to thank Trevor for his twelve years of scientific leadership and contributions to our innovative science—most recently as President of Research & Chief Scientific Officer and as a member of our senior management team,” said Bill Newell, Sutro’s Chief Executive Officer.
  • “Trevor’s scientific vision and commitment enabled the six product candidates currently in the clinic that were discovered, developed and manufactured with our cell-free technology.
  • I am confident that the Sutro team will continue to execute and drive value, and I look forward to contributing to Sutro’s success through participating on its Scientific Advisory Board.”
    Dr. Hallam will transition on May 31, 2023 from the role of President of Research & Chief Scientific Officer to his membership on Sutro’s Scientific Advisory Board.
  • Nicki Vasquez, Ph.D., Chief Portfolio Strategy & Alliance Officer, who is currently a member of the Sutro Senior Management Team, will assume interim responsibility for leading the research organization.